Preclinical evaluation of anti-rheumatic drugs in a non-human primate model of arthritic disease

Drug Discovery Today: Disease Models

Volumn 5, Issue 2, 2008, Pages 89-95

  Vierboom, Michel P M ^a   Breedveld, Elia ^a   't Hart, Bert A ^a,b  

^a BIOMEDICAL PRIMATE RESEARCH CENTRE   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; C REACTIVE PROTEIN; COLLAGEN; CYTOKINE; IMMUNOMODULATING AGENT; MAJOR HISTOCOMPATIBILITY ANTIGEN; PLACEBO;

ANTIGEN ANTIBODY REACTION; ARTHRITIS; AUTOPSY; BONE EROSION; CELLULAR IMMUNITY; CLINICAL FEATURE; CROSS REACTION; CYTOKINE PRODUCTION; DIAGNOSTIC VALUE; DISEASE CLASSIFICATION; DISEASE MARKER; DISEASE MODEL; DISEASE SEVERITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; DRUG SYNTHESIS; DRUG TARGETING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOPATHOLOGY; HUMORAL IMMUNITY; IMMUNOCOMPETENT CELL; IN VITRO STUDY; IN VIVO STUDY; MEDICAL RESEARCH; NON INVASIVE MEASUREMENT; NONHUMAN; PHYSICAL EXAMINATION; PROTEIN BLOOD LEVEL; REVIEW; RHESUS MONKEY; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SINGLE DRUG DOSE; URINALYSIS;

EID: 59249089574     PISSN: 17406757     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddmod.2008.06.003     Document Type: Review

References (30)

1. Choy E.H., and Panayi G.S. Cytokine pathways and joint inflammation in rheumatoid arthritis. N. Engl. J. Med. 344 (2001) 907-916
2. Lee D.M., and Weinblatt M.E. Rheumatoid arthritis. Lancet 358 (2001) 903-911
3. Jacobson D.L., et al. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin. Immunol. Immunopathol. 84 (1997) 223-243
4. Vierboom M.P., et al. Preclinical models of arthritic disease in non-human primates. Drug Discov. Today 12 (2007) 327-335
5. Vierboom M.P., et al. The significance of non-human primates as preclinical models of human arthritic disease. Expert Opin. Drug Discov. 3 (2008) 299-310
6. Vierboom M.P., et al. Modeling human arthritic diseases in nonhuman primates. Arthritis Res. Ther. 7 (2005) 145-154
7. Booth B., and Zemmel R. Prospects for productivity. Nat. Rev. Drug Discov. 3 (2004) 451-456
8. Frantz S. FDA publishes analysis of the pipeline problem. Nat. Rev. Drug Discov. 3 (2004) 379
9. Chapman K., et al. Preclinical safety testing of monoclonal antibodies: the significance of species relevance. Nat. Rev. Drug Discov. 6 (2007) 120-126
10. Helsinki, D.O. (1964) Declaration of Helsinki (2000 version). http://www.wma.net/e/policy/b3.htm
11. (2002) 'The FDA animal efficacy rule'. http://www.hhs.gov/nvpo/policy_reg.html
12. Contag P.R. Whole-animal cellular and molecular imaging to accelerate drug development. Drug Discov. Today 7 (2002) 555-562
13. Bakker N.P., et al. Collagen-induced arthritis in an outbred group of rhesus monkeys comprising responder and nonresponder animals. Relationship between the course of arthritis and collagen-specific immunity. Arthritis Rheum 34 (1991) 616-624
14. Bakker N.P., et al. Resistance to collagen-induced arthritis in a nonhuman primate species maps to the major histocompatibility complex class I region. J. Exp. Med. 175 (1992) 933-937
15. Otting N., et al. Unparalleled complexity of the MHC class I region in rhesus macaques. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 1626-1631
16. Tillet W., and Francis T. Serological reactions in pneumonia with a nonprotein fraction from pneumococcus. J. Exp. Med. 52 (1930) 561-571
17. van Gaalen F.A., et al. Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis Rheum 50 (2004) 709-715
18. Black D., et al. Quantitative analysis of the pyridinium crosslinks of collagen in urine using ion-paired reversed-phase high-performance liquid chromatography. Anal. Biochem. 169 (1988) 197-203
19. Pettit A.R., et al. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am. J. Pathol. 159 (2001) 1689-1699
20. Arnett H.A., and Viney J.L. Considerations for the sensible use of rodent models of inflammatory disease in predicting efficacy of new biological therapeutics in the clinic. Adv. Drug Deliv. Rev. 59 (2007) 1084-1092
21. Bendele A. Animal models of rheumatoid arthritis. J. Musculoskelet. Neuronal. Interact. 1 (2001) 377-385
22. Kannan K., et al. Animal models of rheumatoid arthritis and their relevance to human disease. Pathophysiology 12 (2005) 167-181
23. Lindqvist A.-K., et al. Mouse models for rheumatoid arthritis. Trends Genet. 18 (2002) S7-S13
24. Sakaguchi S., and Sakaguchi N. Animal models of arthritis caused by systemic alteration of the immune system. Curr. Opin. Immunol. 17 (2005) 589-594
25. Arnett F.C., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 31 (1988) 315-324
26. 't Hart B.A., et al. Collagen-induced arthritis in rhesus monkeys: evaluation of markers for inflammation and joint degradation. Br. J. Rheumatol. 37 (1998) 314-323
27. Ou L.S., et al. Association between serum inflammatory cytokines and disease activity in juvenile idiopathic arthritis. Clin. Rheumatol. 21 (2002) 52-56
28. Rooney M., et al. Inflammatory cytokine responses in juvenile chronic arthritis. Br. J. Rheumatol. 34 (1995) 454-460
29. 't Hart B.A., et al. Resistance to collagen-induced arthritis in rats and rhesus monkeys after immunization with attenuated type II collagen. Eur. J. Immunol. 23 (1993) 1588-1594
30. Myers L.K., et al. Juvenile arthritis and autoimmunity to type II collagen. Arthritis Rheum 44 (2001) 1775-1781